iCAD, Inc. (ICAD) Reports Growing Adoption And Utilization Of Its Xoft System For Breast And Skin Cancers
11/20/2013 9:19:43 AM
NASHUA, N.H.--(BUSINESS WIRE)--iCAD, Inc. (Nasdaq: ICAD), a leading provider of advanced imaging and radiation therapy for the early identification and treatment of cancer, today announced growing demand, adoption and clinical evidence for its Xoft® Axxent® Electronic Brachytherapy System® for the treatment of early-stage breast cancer and non-melanoma skin cancer.
Help employers find you! Check out all the jobs and post your resume.
comments powered by